Flux RSS des communiqués de presse de la société Eli Lilly and Company Follow Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting investor.lilly.com
